BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 18580230)

  • 1. The added benefit of a dedicated neck F-18 FDG PET-CT imaging protocol in patients with suspected recurrent differentiated thyroid carcinoma.
    Davison JM; Stocker DJ; Montilla-Soler JL; Jurgens JS; Allen TW; Holley TS; Stack AL
    Clin Nucl Med; 2008 Jul; 33(7):464-8. PubMed ID: 18580230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent thyroid cancer diagnosis: ROC study of the effect of a high-resolution head and neck 18F-FDG PET/CT scan.
    Chatziioannou SN; Georgakopoulos AT; Pianou NK; Kafiri GT; Pavlou SN; Kallergi M
    Acad Radiol; 2014 Jan; 21(1):58-63. PubMed ID: 24331265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.
    Weber T; Ohlhauser D; Hillenbrand A; Henne-Bruns D; Reske SN; Luster M
    Horm Metab Res; 2012 Nov; 44(12):904-8. PubMed ID: 22791600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of neck recurrence in patients with differentiated thyroid cancer: comparison of ultrasound, contrast-enhanced CT and (18)F-FDG PET/CT using surgical pathology as a reference standard: (ultrasound vs. CT vs. (18)F-FDG PET/CT in recurrent thyroid cancer).
    Seo YL; Yoon DY; Baek S; Ku YJ; Rho YS; Chung EJ; Koh SH
    Eur Radiol; 2012 Oct; 22(10):2246-54. PubMed ID: 22562091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer.
    Alzahrani AS; Abouzied ME; Salam SA; Mohamed G; Rifai A; Al Sugair A; Amin T
    Eur J Endocrinol; 2008 May; 158(5):683-9. PubMed ID: 18426827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental Value of a Dedicated Head and Neck Acquisition during 18F-FDG PET/CT in Patients with Differentiated Thyroid Cancer.
    Ciappuccini R; Aide N; Blanchard D; Rame JP; de Raucourt D; Michels JJ; Babin E; Bardet S
    PLoS One; 2016; 11(9):e0162482. PubMed ID: 27598385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. F-18 FDG PET/CT in the management of thyroid cancer.
    Iagaru A; Kalinyak JE; McDougall IR
    Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer.
    Yi JG; Marom EM; Munden RF; Truong MT; Macapinlac HA; Gladish GW; Sabloff BS; Podoloff DA
    Radiology; 2005 Jul; 236(1):271-5. PubMed ID: 15987980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head and neck cancer: dedicated FDG PET/CT protocol for detection--phantom and initial clinical studies.
    Yamamoto Y; Wong TZ; Turkington TG; Hawk TC; Coleman RE
    Radiology; 2007 Jul; 244(1):263-72. PubMed ID: 17495174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
    Jadvar H; Henderson RW; Conti PS
    J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma.
    Mirallié E; Guillan T; Bridji B; Resche I; Rousseau C; Ansquer C; Bodet-Milin C; Curtet C; Carnaille B; Murat A; Charbonnel B; Kraeber-Bodéré F
    Surgery; 2007 Dec; 142(6):952-8; discussion 952-8. PubMed ID: 18063081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.
    Pryma DA; Schöder H; Gönen M; Robbins RJ; Larson SM; Yeung HW
    J Nucl Med; 2006 Aug; 47(8):1260-6. PubMed ID: 16883003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
    Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N
    J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy of ultrasound and 18-F-FDG PET or PET/CT for patients with suspected recurrent papillary thyroid carcinoma.
    Choi JW; Lee JH; Baek JH; Choi BS; Jeong KS; Ryu JS; Kim TY; Kim WB; Shong YK
    Ultrasound Med Biol; 2010 Oct; 36(10):1608-15. PubMed ID: 20850026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors.
    Scanga DR; Martin WH; Delbeke D
    Clin Nucl Med; 2004 Feb; 29(2):86-90. PubMed ID: 14734903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans.
    Ong SC; Ng DC; Sundram FX
    Singapore Med J; 2005 Jun; 46(6):297-301. PubMed ID: 15902358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.
    Giraudet AL; Vanel D; Leboulleux S; Aupérin A; Dromain C; Chami L; Ny Tovo N; Lumbroso J; Lassau N; Bonniaud G; Hartl D; Travagli JP; Baudin E; Schlumberger M
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4185-90. PubMed ID: 17726071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis.
    Haslerud T; Brauckhoff K; Reisæter L; Küfner Lein R; Heinecke A; Varhaug JE; Biermann M
    Acta Radiol; 2016 Oct; 57(10):1193-200. PubMed ID: 26163534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.